Medically reviewed content · Last updated April 2026

LDL Cholesterol: What Your GP Doesn’t Have Time to Explain

You got a blood test. Your LDL cholesterol came back high. Your GP said something about “lifestyle changes” and possibly mentioned statins. The appointment lasted ten minutes. You left with more questions than answers.

This is one of the most common experiences in UK primary care. Cholesterol is the most frequently tested biomarker in the NHS, yet the conversation around results is almost always oversimplified. You are told your LDL is “high” and you should lower it. But nobody explains why LDL matters, what the different types of LDL mean, which other markers actually predict heart disease better, or why the dietary advice you have been given for decades is largely wrong.

This guide goes deeper than your GP has time to. We cover LDL-C versus LDL-P versus ApoB (and which one actually matters), the difference between small dense and large buoyant LDL particles, why the triglyceride-to-HDL ratio may be a better predictor of cardiovascular risk than LDL alone, the hidden risk factor your GP has probably never tested, the statins debate, and what you should actually do about a high cholesterol result.

Understanding Cholesterol: The Basics Your GP Assumes You Know

Cholesterol itself is not the villain it has been made out to be. It is a waxy, fat-like molecule that your body produces naturally and needs for critical functions: building cell membranes, producing hormones (including oestrogen, testosterone, and cortisol), synthesising vitamin D, and creating bile acids for digestion. Around 80% of the cholesterol in your blood is manufactured by your liver; only about 20% comes from what you eat.

Because cholesterol is fat-soluble, it cannot travel through your water-based blood on its own. It needs to be packaged into particles called lipoproteins — essentially spherical containers made of protein and fat that ferry cholesterol and triglycerides around your body. The two you hear about most are:

• LDL (low-density lipoprotein): Carries cholesterol from the liver to tissues. The one labelled “bad” cholesterol.
• HDL (high-density lipoprotein): Carries cholesterol from tissues back to the liver for disposal. The one labelled “good” cholesterol.

This good/bad framing is massively oversimplified, as we will see. But it is the framework your GP works with, and it shapes the advice you receive.

LDL-C vs LDL-P vs ApoB: Which Actually Matters?

LDL-C (LDL Cholesterol)

This is what your standard NHS lipid panel measures. LDL-C tells you the mass of cholesterol carried inside your LDL particles, expressed in mmol/L. The NHS reference ranges are:

The problem with LDL-C is that it measures cargo, not vehicles. Imagine two delivery fleets carrying identical amounts of goods. Fleet A uses 100 small vans. Fleet B uses 50 large lorries. The total cargo is the same (same LDL-C), but Fleet A creates far more traffic, congestion, and wear on the roads. In your arteries, more particles means more opportunities for those particles to penetrate the arterial wall, oxidise, and trigger the inflammatory cascade that creates plaque. The number of particles matters more than the total cholesterol they carry.

LDL-P (LDL Particle Number)

LDL-P counts the actual number of LDL particles in your blood. This is closer to what matters for cardiovascular risk because each particle — regardless of how much cholesterol it carries — has the potential to enter your arterial wall and contribute to atherosclerosis.

The discordance between LDL-C and LDL-P is clinically significant. Studies including the Framingham Offspring Study and MESA (Multi-Ethnic Study of Atherosclerosis) have shown that when LDL-C and LDL-P disagree, cardiovascular risk follows particle number, not cholesterol content. A person with normal LDL-C but high LDL-P has elevated risk. A person with high LDL-C but low LDL-P has lower risk than their cholesterol number suggests.

Unfortunately, LDL-P is not routinely available in the UK. It requires NMR (nuclear magnetic resonance) spectroscopy, which is expensive and offered by very few laboratories. This is where ApoB comes in.

ApoB (Apolipoprotein B)

ApoB is the protein that wraps around every atherogenic lipoprotein particle — every LDL, every VLDL, every IDL, and every Lp(a) particle carries exactly one ApoB molecule. This makes ApoB a direct, countable measure of the total number of particles that can contribute to atherosclerosis.

Why ApoB is the superior marker:

• It counts all atherogenic particles, not just LDL
• It is unaffected by particle size variation (unlike LDL-C)
• It is a stronger predictor of cardiovascular events than LDL-C in head-to-head studies
• It is available through standard laboratory assays — no special equipment needed
• It resolves the LDL-C/LDL-P discordance problem

Optimal ApoB ranges:

• Low risk: <1.0 g/L
• Moderate risk: <0.8 g/L
• High risk / established CVD: <0.65 g/L
• Longevity-focused optimal: <0.7 g/L

The European Atherosclerosis Society and the Canadian Cardiovascular Society now recommend ApoB as a primary target for lipid management. NICE in the UK has been slower to adopt this, which means your GP is likely still focused exclusively on LDL-C. A private blood test that includes ApoB gives you a significantly more accurate picture of your actual cardiovascular risk.

Small Dense vs Large Buoyant LDL: Size Matters

Not all LDL particles are equal. They vary in size from small, dense particles (called Pattern B) to large, buoyant particles (Pattern A). This distinction is important because small dense LDL particles are substantially more atherogenic:

• They penetrate arterial walls more easily due to their smaller diameter
• They oxidise more readily, and it is oxidised LDL that triggers the inflammatory response that creates plaque
• They have a longer circulation time (3–5 days vs 2 days for large particles), giving them more opportunities to enter the arterial wall
• They bind less effectively to LDL receptors, meaning your liver clears them more slowly

The practical implication: a person with an LDL-C of 4.0 mmol/L composed primarily of large buoyant particles may have lower cardiovascular risk than a person with an LDL-C of 3.0 mmol/L composed primarily of small dense particles. The total cholesterol number is misleading without particle size context.

What drives small dense LDL? The biggest culprit is metabolic dysfunction — specifically insulin resistance, high triglycerides, visceral fat, and a diet high in refined carbohydrates and sugar. This is one of the reasons the triglyceride:HDL ratio is so informative.

The Triglyceride:HDL Ratio — A Better Predictor You Already Have

If you have a standard lipid panel, you already have the data to calculate one of the most powerful cardiovascular risk indicators available — and it is free.

Triglyceride:HDL ratio = Triglycerides ÷ HDL (both in mmol/L)

Research published in Circulation and JAMA has consistently shown that the triglyceride:HDL ratio correlates strongly with insulin resistance, small dense LDL dominance, and cardiovascular event risk — often more strongly than LDL-C alone. The Harvard Physicians’ Health Study found that men with the highest triglyceride:HDL ratios had 16 times the risk of heart attack compared to those with the lowest.

Example: A patient with an LDL-C of 4.5 mmol/L (high), triglycerides of 0.7 mmol/L (low), and HDL of 1.8 mmol/L (high) has a triglyceride:HDL ratio of 0.39 — excellent. This pattern strongly suggests large buoyant LDL particles and low cardiovascular risk, despite the “high” LDL-C. A GP looking only at LDL-C might recommend statins; a deeper analysis suggests this person is metabolically healthy.

Lp(a): The Hidden Risk Factor

Lipoprotein(a) — written as Lp(a) and pronounced “L-P-little-a” — may be the single most important cardiovascular risk factor that your GP has never tested. It is a genetically determined lipoprotein particle that carries additional risk beyond what LDL-C captures.

Key facts about Lp(a):

• Levels are 90%+ determined by genetics. You inherit your Lp(a) level, and it remains largely stable throughout life.
• Elevated Lp(a) (above 75 nmol/L or 30 mg/dL) affects approximately 20% of the global population.
• High Lp(a) independently increases cardiovascular risk 2–3 fold. It promotes atherosclerosis, thrombosis, and inflammation.
• It is not reduced by diet, exercise, or statin therapy. Statins may actually increase Lp(a) slightly.
• PCSK9 inhibitors reduce Lp(a) by approximately 20–30%, and a dedicated Lp(a)-lowering drug (pelacarsen/olpasiran) is in late-stage clinical trials as of 2026.
• You only need to test Lp(a) once in your lifetime because it is genetically fixed. Yet most people have never had it measured.

Why it matters for your high LDL result: Standard LDL-C includes the cholesterol carried by Lp(a) particles. If your Lp(a) is high, a significant portion of your “LDL-C” may actually be Lp(a) cholesterol, which behaves differently from regular LDL and does not respond to the same interventions. Knowing your Lp(a) changes the clinical picture and may change the treatment approach.

The European Society of Cardiology recommends measuring Lp(a) at least once in every adult’s lifetime. The NHS does not currently include it in standard lipid panels. A private blood test is the most reliable way to get this measurement.

The Statins Debate: What the Evidence Actually Says

Statins are the most prescribed medication in the UK. Over 8 million people take them. The NHS QRISK3 calculator recommends statins for anyone with a 10% or greater 10-year cardiovascular risk — a threshold that includes a large proportion of adults over 60 regardless of their actual cholesterol levels.

What statins do: Statins block HMG-CoA reductase, an enzyme your liver uses to produce cholesterol. This forces your liver to pull more LDL from your blood to meet its cholesterol needs, lowering LDL-C by 30–50%. They also have anti-inflammatory effects independent of cholesterol lowering, which may account for some of their benefit.

Where the evidence is strong:

• Secondary prevention (people who have already had a heart attack or stroke): Statins reduce the risk of a second event by roughly 25–30%. The benefit is clear and well-established.
• High-risk primary prevention (people with familial hypercholesterolaemia, very high ApoB, diabetes with additional risk factors): Significant benefit with NNT (number needed to treat) of 20–40 over 5 years.

Where the evidence is weaker:

• Low-to-moderate risk primary prevention (healthy people with slightly elevated cholesterol): The absolute risk reduction is small. For a healthy person with a 10% ten-year risk, statins reduce that to roughly 7–8%. The NNT is 50–100+ over 5 years, meaning you need to treat 50–100 people for 5 years to prevent one cardiovascular event.
• Women are underrepresented in statin trials. The primary prevention benefit in women without diabetes is less clearly demonstrated than in men.
• Elderly patients (over 75) without existing CVD: limited trial data for primary prevention.

Side effects to consider: Muscle pain (myalgia) affects 5–10% of statin users in real-world studies (higher than in clinical trials). Statins can raise blood glucose and slightly increase Type 2 diabetes risk. Cognitive complaints are reported but less well-established. Most side effects resolve on stopping the medication or switching to a different statin.

The balanced view: Statins are a valuable tool in the right context. The problem is not statins themselves but the oversimplified framework that treats LDL-C as the only variable. A person with high LDL-C, low ApoB, low triglycerides, high HDL, normal Lp(a), and low hs-CRP has a very different risk profile from a person with the same LDL-C but high ApoB, high triglycerides, low HDL, elevated Lp(a), and raised hs-CRP. The first person may not benefit meaningfully from a statin. The second almost certainly will.

Dietary Cholesterol vs Blood Cholesterol: What Actually Moves the Needle

For decades, the UK public was told to avoid eggs, shellfish, and saturated fat to keep cholesterol down. This advice was based on a plausible but ultimately incomplete hypothesis: dietary cholesterol raises blood cholesterol, which causes heart disease.

The reality is more nuanced:

Dietary cholesterol has minimal impact for most people. Your body tightly regulates cholesterol production. When you eat more cholesterol, your liver produces less. When you eat less, it produces more. For approximately 75% of the population (“hypo-responders”), eating cholesterol-rich foods has little effect on blood cholesterol. For the remaining 25% (“hyper-responders”), dietary cholesterol does raise both LDL and HDL, but the ratio often stays the same or improves.

What actually worsens your lipid profile:

• Refined carbohydrates and sugar: Drive triglyceride production, lower HDL, promote small dense LDL, and worsen insulin resistance. This is the single biggest dietary driver of an atherogenic lipid profile.
• Trans fats: Raise LDL, lower HDL, increase inflammation. Largely eliminated from UK food supply but still present in some processed foods.
• Excessive omega-6 seed oils: Soybean, sunflower, corn, and rapeseed oils in large quantities may promote inflammation and oxidation of LDL particles. The evidence is debated but sufficient to warrant moderation.
• Excess alcohol: Raises triglycerides significantly. Even moderate drinking (14 units/week, UK guideline) can elevate triglycerides.

What actually improves your lipid profile:

• Reducing refined carbohydrates: The single most effective dietary change for lowering triglycerides, raising HDL, and shifting LDL particles from small dense to large buoyant.
• Omega-3 fatty acids: Oily fish (salmon, mackerel, sardines), fish oil supplements. Reduce triglycerides by 15–30% and have anti-inflammatory effects.
• Soluble fibre: Oats, beans, lentils, psyllium husk. Reduces LDL-C by 5–10% by binding bile acids in the gut.
• Exercise: Regular moderate-to-vigorous exercise raises HDL, lowers triglycerides, and improves particle size distribution.
• Weight loss (if overweight): Losing 5–10% of body weight significantly improves triglycerides, HDL, particle size, and insulin sensitivity.
• Extra virgin olive oil: Rich in polyphenols that reduce LDL oxidation — one of the key mechanisms of atherosclerosis.

What to Actually Do About High LDL

If you have received a high LDL-C result, here is a step-by-step framework for understanding and acting on it:

1. Get the full picture. Request or privately test: ApoB, full lipid panel (total cholesterol, LDL-C, HDL, triglycerides), Lp(a), hs-CRP, HbA1c, fasting glucose, and fasting insulin. Without these, LDL-C alone is an incomplete risk assessment.
2. Calculate your triglyceride:HDL ratio. If it is below 1.0 (mmol/L), your LDL particles are likely large and buoyant — a lower-risk pattern. If it is above 2.0, you likely have small dense LDL dominance and metabolic dysfunction that needs addressing.
3. Check Lp(a). One test, once in your life. If elevated, this changes your risk calculation and may justify earlier or more aggressive intervention regardless of LDL-C.
4. Assess metabolic health. Are your HbA1c, fasting glucose, fasting insulin, and waist circumference normal? If you are metabolically healthy (normal blood sugar, normal insulin, normal waist circumference, normal triglycerides, high HDL), a mildly elevated LDL-C is less concerning than if you have metabolic syndrome features.
5. Address root causes first. Reduce refined carbohydrates and sugar. Increase omega-3 intake. Add soluble fibre. Exercise regularly. Manage stress (cortisol raises cholesterol). Optimise sleep (poor sleep raises LDL-C and triglycerides). These interventions improve the entire lipid profile, not just LDL-C.
6. Retest in 3–6 months. If lifestyle changes improve your ApoB, triglyceride:HDL ratio, and hs-CRP, your actual cardiovascular risk has decreased meaningfully — even if LDL-C has not changed much.
7. Discuss statins with full data. If your ApoB remains elevated, your Lp(a) is high, you have metabolic dysfunction, or you have a family history of early cardiovascular disease, statins (or alternative lipid-lowering therapy) may be appropriate. The conversation is far more productive when you bring objective data beyond just LDL-C.

The Markers Your GP Should Be Testing (But Probably Isn’t)

A comprehensive private blood test that includes all of these markers, alongside the standard lipid panel, gives you a cardiovascular risk assessment that is significantly more accurate than LDL-C alone. For related reading on what comprehensive blood testing reveals, see our guides on blood tests for fatigue and health checks over 40.

Frequently Asked Questions

Is high LDL cholesterol always dangerous?

Not necessarily. LDL-C measures the cholesterol content of LDL particles, but cardiovascular risk depends more on particle number (ApoB), particle size (small dense vs large buoyant), and the broader metabolic context. A person with high LDL-C but low triglycerides, high HDL, low ApoB, normal Lp(a), and low inflammatory markers (hs-CRP) may have lower cardiovascular risk than someone with moderate LDL-C but a poor metabolic profile. This is why a comprehensive panel is essential for accurate risk assessment.

Should I stop eating eggs if my cholesterol is high?

For most people, no. Dietary cholesterol from eggs has minimal impact on blood cholesterol. Your liver compensates by reducing its own cholesterol production when you eat more. Meta-analyses published in the BMJ and American Journal of Clinical Nutrition have found no significant association between egg consumption and cardiovascular disease in healthy individuals. Refined carbohydrates, sugar, and trans fats have a far greater impact on your lipid profile than dietary cholesterol. If you are a hyper-responder (about 25% of people), eggs may raise both LDL and HDL, but the ratio often remains stable.

What is ApoB and why should I care about it?

Apolipoprotein B (ApoB) is the protein that wraps around every atherogenic lipoprotein particle. Each LDL, VLDL, IDL, and Lp(a) particle carries exactly one ApoB molecule, making it a direct count of the total number of particles that can contribute to atherosclerosis. Multiple large studies have shown ApoB is a stronger predictor of cardiovascular events than LDL-C. The European Atherosclerosis Society recommends ApoB as a primary target for lipid management. It is not included in standard NHS lipid panels but is available through private blood testing.

Can I lower my cholesterol without statins?

Yes, many people can improve their lipid profile significantly through lifestyle changes alone. Reducing refined carbohydrates and sugar lowers triglycerides and shifts LDL particles from small dense to large buoyant. Omega-3 fatty acids from oily fish reduce triglycerides by 15–30%. Soluble fibre (oats, beans, psyllium) reduces LDL-C by 5–10%. Regular exercise raises HDL and improves particle size. Weight loss of 5–10% improves nearly all lipid markers. However, if you have familial hypercholesterolaemia, elevated Lp(a), or established cardiovascular disease, medication may be necessary alongside lifestyle changes.

What is Lp(a) and should I get tested?

Lipoprotein(a) is a genetically determined lipoprotein particle that independently increases cardiovascular risk 2–3 fold when elevated. It affects approximately 1 in 5 people and cannot be lowered by diet, exercise, or statins. The European Society of Cardiology recommends measuring Lp(a) at least once in every adult’s lifetime. Since levels are genetically fixed, you only need one test. Most GPs do not routinely test Lp(a), but it is available through private blood testing and can fundamentally change your understanding of your cardiovascular risk.

What triglyceride:HDL ratio should I aim for?

In mmol/L units (standard in the UK), a triglyceride:HDL ratio below 1.0 is excellent and suggests predominantly large buoyant LDL particles. Between 1.0 and 1.5 is good. Above 2.0 suggests metabolic dysfunction with small dense LDL dominance. You can calculate this from any standard lipid panel. It is a simple, free indicator of your metabolic health and cardiovascular risk that many consider more useful than LDL-C alone.